The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...

Harmful variants in the BRCA1 gene greatly increase a person's lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

ROANOKE, Va. – It’s estimated that more than 42,000 people will die from breast cancer this year, according to the American Cancer Society. To help you understand if you’re at a greater risk of ...

Primary care providers should screen women for personal, family and/or ethnic history of breast, ovarian, tubal or peritoneal cancer to decide who should undergo genetic counseling for BRCA1 and BRCA2 ...

Not only do home genetic test kits, like 23andMe, provide information about your ancestry, but they can also give you some insights into your inherited health risks, particularly mutations on the BRCA ...

Prospective screening for Lynch syndrome (LS) in a cohort of colorectal cancer (CRC) surgical patients in a community hospital. Background: A BRCA1 gene mutation is well-known risk factor for breast ...

An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...

Harmful variants in the BRCA1 gene greatly increase a person’s lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

Pathway Genomics said that it has launched BRCATrue, a next- generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian ...

In May 2013, nearly 20 years after the discovery that mutations on the BRCA1 and BRCA2 genes could lead to a higher risk of breast and ovarian cancer, A-list Hollywood actress Angelina Jolie garnered ...

Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.